ASX:CUV

Clinuvel Pharmaceuticals Competitors

Add

Compare

Today's Range N/A

50-Day Range

A$23.00

MA: A$23.00▼

A$23.00

52-Week Range N/A

Volume124,193 shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend Yield0.10%

BetaN/A

Clinuvel Pharmaceuticals (ASX:CUV) Vs. CHV, DDXS, PREV, TNGN, COM, and MYM

Should you be buying CUV stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Clinuvel Pharmaceuticals, including (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), and 17031 (MYM).

Clinuvel Pharmaceuticals vs. (CHV) Stock

Clinuvel Pharmaceuticals (ASX:CUV) and (CHV) (CNSX:CHV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Profitability

This table compares Clinuvel Pharmaceuticals and (CHV)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clinuvel Pharmaceuticals	N/A	N/A	N/A
(CHV)	N/A	N/A	N/A

Valuation & Earnings

This table compares Clinuvel Pharmaceuticals and (CHV)'s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clinuvel Pharmaceuticals	$38.34 million	0.00	$22.04 million	A$0.45	N/A
(CHV)	N/A	N/A	N/A	N/A	N/A

Clinuvel Pharmaceuticals has higher revenue and earnings than (CHV).

Analyst Recommendations

This is a breakdown of recent recommendations for Clinuvel Pharmaceuticals and (CHV), as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clinuvel Pharmaceuticals	0	0	0	0	N/A
(CHV)	0	0	0	0	N/A

Summary

Clinuvel Pharmaceuticals beats (CHV) on 1 of the 1 factors compared between the two stocks.

Clinuvel Pharmaceuticals vs. (DDXS) Stock

Clinuvel Pharmaceuticals (ASX:CUV) and (DDXS) (OTCMKTS:DDXS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Profitability

This table compares Clinuvel Pharmaceuticals and (DDXS)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clinuvel Pharmaceuticals	N/A	N/A	N/A
(DDXS)	N/A	N/A	N/A

Valuation & Earnings

This table compares Clinuvel Pharmaceuticals and (DDXS)'s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clinuvel Pharmaceuticals	$38.34 million	0.00	$22.04 million	A$0.45	N/A
(DDXS)	N/A	N/A	N/A	N/A	N/A

Clinuvel Pharmaceuticals has higher revenue and earnings than (DDXS).

Analyst Recommendations

This is a breakdown of recent recommendations for Clinuvel Pharmaceuticals and (DDXS), as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clinuvel Pharmaceuticals	0	0	0	0	N/A
(DDXS)	0	0	0	0	N/A

Summary

Clinuvel Pharmaceuticals beats (DDXS) on 1 of the 1 factors compared between the two stocks.

Clinuvel Pharmaceuticals vs. (PREV) Stock

Clinuvel Pharmaceuticals (ASX:CUV) and (PREV) (CNSX:PREV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares Clinuvel Pharmaceuticals and (PREV)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clinuvel Pharmaceuticals	N/A	N/A	N/A
(PREV)	N/A	N/A	N/A

Valuation and Earnings

This table compares Clinuvel Pharmaceuticals and (PREV)'s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clinuvel Pharmaceuticals	$38.34 million	0.00	$22.04 million	A$0.45	N/A
(PREV)	N/A	N/A	N/A	N/A	N/A

Clinuvel Pharmaceuticals has higher revenue and earnings than (PREV).

Analyst Ratings

This is a breakdown of recent ratings for Clinuvel Pharmaceuticals and (PREV), as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clinuvel Pharmaceuticals	0	0	0	0	N/A
(PREV)	0	0	0	0	N/A

Summary

Clinuvel Pharmaceuticals beats (PREV) on 1 of the 1 factors compared between the two stocks.

Clinuvel Pharmaceuticals vs. (TNGN) Stock

Clinuvel Pharmaceuticals (ASX:CUV) and (TNGN) (OTCMKTS:TNGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares Clinuvel Pharmaceuticals and (TNGN)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clinuvel Pharmaceuticals	N/A	N/A	N/A
(TNGN)	N/A	N/A	N/A

Valuation and Earnings

This table compares Clinuvel Pharmaceuticals and (TNGN)'s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clinuvel Pharmaceuticals	$38.34 million	0.00	$22.04 million	A$0.45	N/A
(TNGN)	N/A	N/A	N/A	N/A	N/A

Clinuvel Pharmaceuticals has higher revenue and earnings than (TNGN).

Analyst Ratings

This is a breakdown of recent ratings for Clinuvel Pharmaceuticals and (TNGN), as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clinuvel Pharmaceuticals	0	0	0	0	N/A
(TNGN)	0	0	0	0	N/A

Summary

Clinuvel Pharmaceuticals beats (TNGN) on 1 of the 1 factors compared between the two stocks.

Clinuvel Pharmaceuticals vs. 138267 (COM.TO) Stock

Clinuvel Pharmaceuticals (ASX:CUV) and 138267 (COM.TO) (TSE:COM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares Clinuvel Pharmaceuticals and 138267 (COM.TO)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clinuvel Pharmaceuticals	N/A	N/A	N/A
138267 (COM.TO)	N/A	N/A	N/A

Valuation and Earnings

This table compares Clinuvel Pharmaceuticals and 138267 (COM.TO)'s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clinuvel Pharmaceuticals	$38.34 million	0.00	C$22.04 million	A$0.45	N/A
138267 (COM.TO)	N/A	N/A	N/A	N/A	N/A

Clinuvel Pharmaceuticals has higher revenue and earnings than 138267 (COM.TO).

Dividends

Clinuvel Pharmaceuticals pays an annual dividend of A$0.03 per share. 138267 (COM.TO) pays an annual dividend of C$0.02 per share. Clinuvel Pharmaceuticals pays out 6.7% of its earnings in the form of a dividend.

Analyst Ratings

This is a breakdown of recent ratings for Clinuvel Pharmaceuticals and 138267 (COM.TO), as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clinuvel Pharmaceuticals	0	0	0	0	N/A
138267 (COM.TO)	0	0	0	0	N/A

Clinuvel Pharmaceuticals vs. 17031 Stock

Clinuvel Pharmaceuticals (ASX:CUV) and 17031 (CNSX:MYM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Valuation and Earnings

This table compares Clinuvel Pharmaceuticals and 17031's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clinuvel Pharmaceuticals	$38.34 million	0.00	C$22.04 million	A$0.45	N/A
17031	N/A	N/A	N/A	N/A	N/A

Clinuvel Pharmaceuticals has higher revenue and earnings than 17031.

Profitability

This table compares Clinuvel Pharmaceuticals and 17031's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clinuvel Pharmaceuticals	N/A	N/A	N/A
17031	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings for Clinuvel Pharmaceuticals and 17031, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clinuvel Pharmaceuticals	0	0	0	0	N/A
17031	0	0	0	0	N/A

Summary

Clinuvel Pharmaceuticals beats 17031 on 1 of the 1 factors compared between the two stocks.